Isis Pharmaceuticals Inc: (NASD: ISIS)

$20.81

0.35 (1.71%)

Volume 906,524

May 21 04:00 PM ET

Zacks Rank: 2-Buy

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		20.28 - 20.85
	
		52wk Low - High
		7.56 - 23.03
	
		Previous Close
		20.46
	
		Avg. Volume
		1,889,812
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		2.08 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		1.11
	
		PE (Forward)
		0.00
	
		Current Year Est.
		-0.86
	
		Quarterly Earnings ESP 
		13.33%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		2
Buy

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Outperform
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		91 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/15/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -0.86
                        
                            Current Quarter Estimate
                            -0.30
                        
                            Most Accurate Estimate
                            -0.26
                        
                            Earnings ESP 
                            13.33%
                        
                            Next Earnings Report Date
                            08-05-2013
                        
                            EPS Last Year
                            -0.56
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Isis Pharmaceuticals, Inc. is a leading genomics-based drug discovery and development company that is focused on RNA.  RNA is a novel target for drug discovery, and Isis has established a dominant position in RNA research.  The company has integrated the expertise in molecular and cellular biology, medicinal chemistry, RNA biochemistry, bioinformatics, pharmacology and clinical development to create two exciting technologies, antisense and Ibis, a robust pipeline of drugs in development and genomics services.   
Full ISIS Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
ISIS Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.30	-0.34	-0.86	-0.83
Number of Estimates	4	4	5	4
Low Estimate	-0.41	-0.43	-1.31	-1.07
High Estimate	-0.24	-0.26	-0.28	NA
Year Ago EPS	-0.01	-0.32	-0.79	-0.86
EPS Growth	-2,900.00%	-5.47%	-8.61%	2.97%

More ISIS Estimates

Average Earnings Estimates for ISIS

EPS Growth for ISIS

Industry Analysis

Name	Symbol	Previous Close
ISIS PHARMACEUT	ISIS	20.46
AETERNA ZENTARS	AEZS	2.06
ANIKA THERAPEUT	ANIK	14.39
GENTIUM SPA-ADR	GENT	8.84
AASTROM BIOSCI	ASTM	0.59
ACHILLION PHARM	ACHN	7.55
ADDEX THERA LTD	ADDXF	6.94
AFFYMAX INC	AFFY	1.27
ALEXION PHARMA	ALXN	100.03
ALKERMES INC	ALKS	31.04

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals

May 16, 2013

Sanofi/REGN Commence Enrollment

May 15, 2013

Isis Gets $3.5M Milestone Payment

May 14, 2013

Celgene Attains 52-Week High

May 14, 2013

Isis Reports In-Line Loss

May 08, 2013

Isis Initiates ISIS-STAT3 Study

May 07, 2013

Positive Opinion on Allergan Candidate

May 06, 2013

Acorda Incurs Loss, Maintains Guidance

May 06, 2013

More ISIS Zacks Commentary

Financials

EPS TTM	-0.56
Sales	102
Net Income	-43
Price/Earnings	NA
Price/Book	10.36
Price/Cash Flow	NA
Price/Sales	17.05

More ISIS Financials

News

ISRG, AHS, USMO, ISIS, MTL, ATVI Are Seasonally Ripe To Go Up In the Next Five Weeks - M2

May 21, 2013

Isis Pharmaceuticals Earnings In Retrospect: Down 5.6% in the Last 13 Days (ISIS) - Comtex Smartrend(R)

May 20, 2013

Isis Pharmaceuticals Q1 net loss decreases - Datamonitor

May 20, 2013

Isis Pharmaceuticals Earnings Hindsight: Down 5.6% in Last 11 Days (ISIS) - Financial News Network Online - Earnings Lookback

May 18, 2013

Isis Pharmaceuticals initiates Phase Ib/IIa hepatocellular carcinoma study - Datamonitor

May 17, 2013

Shares of Isis Pharmaceuticals Receive a Boost, Up 1.5% - Financial News Network Online - Market Movers

May 17, 2013

Isis Pharmaceuticals (ISIS) Could Fall Through $19.94 Support Level - Freshbrewedmedia

May 16, 2013

The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals - Pr Newswire

May 16, 2013

See All News Stories on ISIS

Broker Recommendations

Current ABR	2.14
ABR (Last Week)	2.14
# of recs in ABR	7
Average Target Price	15.67
Industry Rank by ABR	91 out of 265
Rank in Industry	4 out of 156

More ISIS Broker Recommendations

Day Low - High	20.28 - 20.85
52wk Low - High	7.56 - 23.03
Previous Close	20.46
Avg. Volume	1,889,812
Industry	MED-BIOMED/GENE
Market Cap	2.08 B
Div - Yield	0.00 - 0.00
Beta	1.11
PE (Forward)	0.00
Current Year Est.	-0.86
Quarterly Earnings ESP	13.33%

PE (Forward)	NA
PEG Ratio	NA
Current Year Est.	-0.86
Current Quarter Estimate	-0.30
Most Accurate Estimate	-0.26
Earnings ESP	13.33%
Next Earnings Report Date	08-05-2013
EPS Last Year	-0.56
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

Isis Pharmaceuticals Inc: (NASD: ISIS)

$20.81

0.35 (1.71%)

Volume 906,524

May 21 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-BIOMED/GENE

Zacks Commentary

Financials

News

Broker Recommendations